Study examines drug labeling and exposure in infants

Federal legislation encouraging the study of drugs in pediatric patients has resulted in very few labeling changes that include new infant information, according to a study by Matthew M. Laughon, M.D., M.P.H., of the University of North Carolina at Chapel Hill, and colleagues. Neonates (infants up to 28 days of age) are at high risk of drug-related adverse events and their unique physiology makes it hard to extrapolate data on drugs from older patients.